2018年美国心脏协会《右心衰竭的评估和管理》声明解读

2018-08-15 中国全科医学杂志.2018.21(23):2773-2776.

右心衰竭是一种复杂的综合征,包括不同的病因、机制和病理过程。美国心脏协会(AHA)于2018年4 月发布的《右心衰竭的评估和管理》声明对急、慢性右心衰竭的病理生理学、临床表现、评估及管理方面做了详细阐述,本文将总结并分析该声明的核心内容。

中文标题:

2018年美国心脏协会《右心衰竭的评估和管理》声明解读

发布机构:

发布日期:

2018-08-15

简要介绍:

右心衰竭是一种复杂的综合征,包括不同的病因、机制和病理过程。美国心脏协会(AHA)于2018年4 月发布的《右心衰竭的评估和管理》声明对急、慢性右心衰竭的病理生理学、临床表现、评估及管理方面做了详细阐述,本文将总结并分析该声明的核心内容。 

作者: 南方医科大学南方医院心血管内科 谢祥琨 许顶立

拓展指南:心衰相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2018年美国心脏协会《右心衰竭的评估和管理》声明解读)] GetToolGuiderByIdResponse(projectId=1, id=ff7c81c001629aa6, title=2018年美国心脏协会《右心衰竭的评估和管理》声明解读, enTitle=, guiderFrom=中国全科医学杂志.2018.21(23):2773-2776., authorId=null, author=, summary=右心衰竭是一种复杂的综合征,包括不同的病因、机制和病理过程。美国心脏协会(AHA)于2018年4 月发布的《右心衰竭的评估和管理》声明对急、慢性右心衰竭的病理生理学、临床表现、评估及管理方面做了详细阐述,本文将总结并分析该声明的核心内容。 , cover=, journalId=null, articlesId=null, associationId=null, associationName=, associationIntro=, copyright=0, guiderPublishedTime=Wed Aug 15 00:00:00 CST 2018, originalUrl=, linkOutUrl=, content=<div>右心衰竭是一种复杂的综合征,包括不同的病因、机制和病理过程。美国心脏协会(AHA)于2018年4 月发布的《右心衰竭的评估和管理》声明对急、慢性右心衰竭的病理生理学、临床表现、评估及管理方面做了详细阐述,本文将总结并分析该声明的核心内容。 </div> <div><br> </div>作者: 南方医科大学南方医院心血管内科 谢祥琨 许顶立 <div><br> </div> 拓展指南:<strong>与<font color=red>心衰</font>相关指南:</strong><br><ul><li><a href="http://www.medsci.cn/guideline/show_article.do?id=b6d8b1c00159324b" title="2018 营养和饮食学会循证实践指南:心衰患者的管理" target=_blank>2018 营养和饮食学会循证实践指南:心衰患者的管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f124c1c001580e21" title="2018 AHA科学声明:右心衰的评估和管理" target=_blank>2018 AHA科学声明:右心衰的评估和管理</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=a82c61c00156e0c7" title="2018 HFA/ESC立场声明:2型糖尿病和心衰" target=_blank>2018 HFA/ESC立场声明:2型糖尿病和心衰</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=13a191c0015ae861" title="《生物标志物在心衰预防、评估以及管理中的作用》解读" target=_blank>《生物标志物在心衰预防、评估以及管理中的作用》解读</a></li> <li><a href="http://www.medsci.cn/guideline/show_article.do?id=f2b191c0015386d2" title="2017 ACC专家共识:优化心衰治疗的决策路径" target=_blank>2017 ACC专家共识:优化心衰治疗的决策路径</a></li> 更多信息请点击:<a href="http://www.medsci.cn/guideline/list.do?q=%E5%BF%83%E8%A1%B0" target=_blank>有关心衰更多指南</a></ul>, tagList=[TagDto(tagId=61548, tagName=右心衰)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=解读, guiderLanguage=1, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=6592, appHits=502, showAppHits=0, pcHits=5322, showPcHits=1425, likes=145, shares=21, comments=4, approvalStatus=1, publishedTime=Mon Aug 20 19:41:35 CST 2018, publishedTimeString=2018-08-15, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Aug 20 19:41:35 CST 2018, updatedBy=null, updatedName=null, updatedTime=Fri Jan 05 11:45:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2018年美国心脏协会《右心衰竭的评估和管理》声明解读)])
2018年美国心脏协会《右心衰竭的评估和管理》声明解读
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1207624, encodeId=f24b120e624f1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5195714263, createdName=ms7000000112947943, createdTime=Thu Mar 31 18:46:51 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903158, encodeId=50ab90315857, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01ad9749, createdName=archazrael, createdTime=Sat Nov 28 23:04:25 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883556, encodeId=745488355662, content=解读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:47:52 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2022-03-31 ms7000000112947943

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1207624, encodeId=f24b120e624f1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5195714263, createdName=ms7000000112947943, createdTime=Thu Mar 31 18:46:51 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903158, encodeId=50ab90315857, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01ad9749, createdName=archazrael, createdTime=Sat Nov 28 23:04:25 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883556, encodeId=745488355662, content=解读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:47:52 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-11-28 archazrael

    学习了

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1207624, encodeId=f24b120e624f1, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e5195714263, createdName=ms7000000112947943, createdTime=Thu Mar 31 18:46:51 CST 2022, time=2022-03-31, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=903158, encodeId=50ab90315857, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=85, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=01ad9749, createdName=archazrael, createdTime=Sat Nov 28 23:04:25 CST 2020, time=2020-11-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883556, encodeId=745488355662, content=解读, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210524/55f15b58d91d45c09faf0272721b59d8/b8f36c2def38403ab9fdabaae56a939c.jpg, createdBy=f0935399328, createdName=ms1000000302953060, createdTime=Tue Sep 08 10:47:52 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-08 ms1000000302953060

    解读

    0